FindTrial
Sign In

A clinical study to evaluate the role of germline genomic etiology combined with imaging in risk assessment, very early prevention and diagnosis of breast cancer

A clinical study to evaluate the role of germline genomic etiology combined with imaging in risk assessment, very early prevention and diagnosis of breast cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064085
Enrollment
Unknown
Registered
2022-09-26
Start date
2022-10-08
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:Pathological diagnosis
Index test:APSP, MR, ultrasound,X ray

Sponsors

Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Female patients aged 18 to 75 at the time of signing the informed consent form. 2. ECOG score 0 or 1.

Exclusion criteria

Exclusion criteria: Previously diagnosed as breast cancer.

Design outcomes

Primary

MeasureTime frame
Activity Profiles of Signalling Pathways;Incidence of breast cancer;—

Secondary

MeasureTime frame
breast precancerous lesion;—

Countries

China

Contacts

Public ContactMei Yang

Guangdong Provincial People's Hospital

yangmei286@163.com13725421149

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026